Growth Metrics

Insulet (PODD) EBIAT (2016 - 2026)

Insulet filings provide 16 years of EBIAT readings, the most recent being $101.6 million for Q4 2025.

  • On a quarterly basis, EBIAT rose 0.89% to $101.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $247.1 million, a 40.93% decrease, with the full-year FY2025 number at $247.1 million, down 40.93% from a year prior.
  • EBIAT hit $101.6 million in Q4 2025 for Insulet, up from $87.6 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $188.6 million in Q2 2024 to a low of -$35.0 million in Q2 2022.
  • Median EBIAT over the past 5 years was $29.2 million (2021), compared with a mean of $47.0 million.
  • Biggest five-year swings in EBIAT: plummeted 273.61% in 2021 and later skyrocketed 1098.08% in 2023.
  • Insulet's EBIAT stood at $29.2 million in 2021, then tumbled by 41.78% to $17.0 million in 2022, then soared by 507.65% to $103.3 million in 2023, then decreased by 2.52% to $100.7 million in 2024, then grew by 0.89% to $101.6 million in 2025.
  • The last three reported values for EBIAT were $101.6 million (Q4 2025), $87.6 million (Q3 2025), and $22.5 million (Q2 2025) per Business Quant data.